Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

MEDI7247

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

DNA replication inhibitor, SLC1A5-targeted antibody-drug conjugate

Related drugs:

‹

›

SLC1A5 overexpression	Multiple Myeloma	SLC1A5 overexpression	Multiple Myeloma	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D
SLC1A5 overexpression	Burkitt Lymphoma	SLC1A5 overexpression	Burkitt Lymphoma	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D
SLC1A5 underexpression	B Acute Lymphoblastic Leukemia	SLC1A5 underexpression	B Acute Lymphoblastic Leukemia	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D
SLC1A5 expression	Multiple Myeloma	SLC1A5 expression	Multiple Myeloma	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D
SLC1A5 underexpression	Acute Myelogenous Leukemia	SLC1A5 underexpression	Acute Myelogenous Leukemia	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D
SLC1A5 overexpression	Acute Myelogenous Leukemia	SLC1A5 overexpression	Acute Myelogenous Leukemia	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D